A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study

Cantaert, Tineke; Borand, Laurence; Kergoat, Lauriane; Leng, Chanthy; Ung, Sivlin; In, Sotheary; Peng, Yiksing; Phoeun, Chandara; Hing, Chanthy; Taing, Chun Navy; Saman, Manil; Ong, Sivuth; Mey, Channa; Choeung, Rithy; Ly, Sowath; Dussart, Philippe; Bourhy, Hervé; Tarantola, Arnaud

doi:10.1016/s1473-3099(19)30311-1

Cited by 21 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies were undertaken in The Philippines [40,50,52], and one included long-term follow up to year 5 [31,50]. The remainder were undertaken in Lithuania, the UK, and Cambodia [41,49,53]. Table S2 (Supplementary Materials) summarizes the details of the studies identified.…”

Section: Immunogenicity Of Pep Regimensmentioning

confidence: 99%

“…No studies were undertaken specifically in children alone; 13 studies included children and adults [25,33,34,[38][39][40][45][46][47][50][51][52][53] or did not specify the age group [42], and the rest were in adults only. These studies were mainly undertaken in patients/participants without prior rabies vaccine experience (prior rabies vaccine experience was usually an exclusion criterion in these studies, except in three studies [28,32,33]).…”

Section: Immunogenicity Of Pep Regimensmentioning

confidence: 99%

“…Ten studies assessed simulated PEP in otherwise healthy participants with no prior rabies vaccination history [25,26,36,38,41,43,44,48,49,53]; these included one study where rabies vaccination history was not stated, but participants had no detectable RVNA at baseline [36], and one study in hemodialysis patients with no previous history of rabies vaccination [44]. The ID PVRV PEP vaccination schedule assessed varied considerably across studies ( Table 1).…”

Section: Immunogenicity Up To 1 Yearmentioning

confidence: 99%

“…All participants in these studies were seroconverted by day 14 to 28 after the first vaccination, with reported GMTs ranging from 3.2 to 26.1 IU/mL [25,26,36,38,41,43,44,48]. Figure 3 summarizes the RVNA GMTs reported across these studies (Cantaert et al reported median titers and are not included [53]). Warrell et al 2008 reported GMTs ranging from 308-364 IU/mL at day 14 [49], which seem to be outlying data values compared to other studies and are not included in the ranges reported overall.…”

Section: Immunogenicity Up To 1 Yearmentioning

confidence: 99%

See 3 more Smart Citations

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

et al. 2020

View full text Add to dashboard Cite

The purified Vero cell rabies vaccine (PVRV; Verorab ® , Sanofi Pasteur) has been used in rabies prevention since 1985. Evolving rabies vaccination trends, including shorter intradermal (ID) regimens with reduced volume, along with WHO recommendation for ID administration has driven recent ID PVRV regimen assessments. Thus, a consolidated review comparing immunogenicity of PVRV ID regimens during pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is timely and beneficial in identifying gaps in current research. A search of seven databases for studies published from 1985 to November 2019 identified 35 studies. PrEP was assessed in 10 studies (n = 926) with 1-3-site, 1-3-visit regimens of up to 3-months duration. Seroconversion (rabies virus neutralizing antibodies [RVNA] ≥ 0.5 IU/mL) rates of 90-100% were reported within weeks, irrespective of regimen, with robust booster responses at 1 year (100% seroconversion rates by day 14 post-booster). However, data are lacking for the current WHO-recommended, 2-site, 1-week ID PrEP regimen. PEP was assessed in 25 studies (n = 2136) across regimens of 1-week to 90-day duration. All ID PEP regimens assessed induced ≥ 99% seroconversion rates (except in HIV participants) by day 14-28. This review confirms ID PVRV suitability for rabies prophylaxis and highlights the heterogeneity of use in the field.

show abstract

Section: Immunogenicity Of Pep Regimensmentioning

confidence: 99%

Section: Immunogenicity Of Pep Regimensmentioning

confidence: 99%

Section: Immunogenicity Up To 1 Yearmentioning

confidence: 99%

Section: Immunogenicity Up To 1 Yearmentioning

confidence: 99%

See 2 more Smart Citations

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Following the bite of a potentially infected animal, administration of three doses of vaccine over the first week and one dose of Rabies immunoglobulin (RIG) without delay is recommended in order to eliminate the virus before it enters the nervous system 7,8 . Recombinant antibody preparations are preferred over traditional serum-derived polyclonal human or equine RIG, as they can be produced in large scale with minimal batch-to-batch variation ensuring improved safety.…”

mentioning

confidence: 99%

Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein

et al. 2020

Self Cite

View full text Add to dashboard Cite

Rabies virus (RABV) causes fatal encephalitis in more than 59,000 people yearly. Upon the bite of an infected animal, the development of clinical disease can be prevented with postexposure prophylaxis (PEP), which includes the administration of Rabies immunoglobulin (RIG). However, the high cost and limited availability of serum-derived RIG severely hamper its wide use in resource-limited countries. A safe low-cost alternative is provided by using broadly neutralizing monoclonal antibodies (bnAbs). Here we report the X-ray structure of one of the most potent and most broadly reactive human bnAbs, RVC20, in complex with its target domain III of the RABV glycoprotein (G). The structure reveals that the RVC20 binding determinants reside in a highly conserved surface of G, rationalizing its broad reactivity. We further show that RVC20 blocks the acid-induced conformational change required for membrane fusion. Our results may guide the future development of direct antiviral small molecules for Rabies treatment.

show abstract

Lyssaviruses and Rabies Vaccines

Rupprecht¹,

Ertl²

2023

Plotkin's Vaccines

View full text Add to dashboard Cite

A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study

Cited by 21 publications

References 19 publications

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein

Lyssaviruses and Rabies Vaccines

Contact Info

Product

Resources

About